Related Experiment Video
Updated: Jan 11, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Clinical Effects of the Concurrent Ingestion of Rosuvastatin and Magnesium Oxide: A Multicenter, Randomized,
Akio Nakashima1,2, Kaoko Tokura1, Momoko Misaki1
1Department of Pharmacy, Fukuoka University Chikushi Hospital, 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka 818-8502, Japan.
Insights
Concurrent use of rosuvastatin (RSV) and magnesium oxide (MgO) did not significantly affect LDL-C reduction. Simplifying administration improves adherence in patients taking multiple medications.
Area of Science:
- Pharmacology
- Clinical Medicine
- Cardiovascular Research
Background:
- Cardiovascular disease (CVD) is a leading cause of death globally.
- Rosuvastatin (RSV) effectively lowers LDL-C but its absorption is reduced by magnesium oxide (MgO).
- This interaction raises concerns about RSV's clinical efficacy when co-administered with MgO.
Purpose of the Study:
- To evaluate the impact of co-administration versus staggered administration of RSV and MgO on LDL-C levels.
- To assess the effect of administration timing on the efficacy of rosuvastatin therapy.
Main Methods:
- A multicenter, randomized, parallel-group trial comparing simultaneous vs. staggered (≥2h) MgO and RSV administration.
- Collected data on demographics and lipid profiles (LDL-C, total cholesterol, HDL-C, triglycerides) at baseline and 12 weeks.
- Monitored medication adherence, including patients with ≥80% compliance in the final analysis.
Main Results:
- 45 patients completed the study (25 control, 20 intervention) with similar baseline characteristics.
- No significant difference in the rate of LDL-C reduction between the simultaneous and staggered administration groups after 12 weeks (P = 0.9091).
Conclusions:
- Concurrent use of rosuvastatin and magnesium oxide does not significantly alter LDL-C reduction compared to staggered administration.
- Simplifying medication schedules can enhance adherence, especially for elderly patients or those with polypharmacy.
Background:
Cardiovascular disease (CVD) remains a leading global cause of mortality. Statins, particularly rosuvastatin (RSV), are widely used to reduce low-density lipoprotein cholesterol (LDL-C) level and prevent atherosclerotic CVD. RSV is highly liver-selective, hydrophilic, and primarily transported via organic anion transport proteins, rendering it less prone to cytochrome P450-mediated drug interactions. However, the concurrent use with magnesium oxide (MgO), a common antacid and laxative, has been shown to decrease RSV absorption by up to 50%, raising concerns regarding the clinical efficacy of RSV in patients taking MgO.
Methods:
This multicenter, randomized, parallel-group comparative trial included outpatients prescribed both RSV and MgO at Fukuoka University Chikushi and Fukuoka Tokushukai Hospitals. Patients were randomly assigned to the control group with simultaneous administration or the intervention group with staggered administration of MgO at least 2 h after RSV. Data on demographics and serum levels of LDL-C, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were collected at baseline and 12 weeks after study initiation. Medication adherence was monitored using a self-reported medication checklist, and patients with ≥ 80% compliance were included in the final analysis.
Results:
A total of 45 patients, including 25 and 20 patients in the control and intervention groups, respectively, completed the study. The median ages were 78 and 76 years in the control and intervention groups, respectively. The baseline demographics and clinical parameters, including LDL-C, were not significantly different between the two groups. After 12 weeks, the rate of change in LDL-C level was not significantly between the control and intervention groups (P = 0.9091).
Conclusion:
The concurrent use of RSV and MgO did not significantly impact the reduction in LDL-C levels compared with the staggered administration. Simplifying administration without altering efficacy can improve medication adherence, particularly in elderly patients and those with polypharmacy, by reducing treatment complexity.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
01:14Time Course of Drug Effect